AAC
PVLA

Acorn Advisory Capital’s Palvella Therapeutics PVLA Stock Holding History

Acorn Advisory Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-344
Closed -$188K – 58
2018
Q1 		$188K Buy
+344
New +$213K 0.29% 39

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Acorn Advisory Capital's PVLA Position: Q2 2018 in Review

Acorn Advisory Capital sold out of Palvella Therapeutics (PVLA) in Q2 2018, closing a stake of 344 shares — an estimated $188K sold.

Acorn Advisory Capital first reported a position in PVLA in Q1 2018 and held it in 1 quarter. The position peaked at $188K in Q1 2018. 115 funds tracked by Wall St. Rank hold PVLA as of Q2 2018.

  • Acorn Advisory Capital reported no remaining Palvella Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Acorn Advisory Capital sold 344 Palvella Therapeutics shares in Q2 2018, an estimated $188K.
  • Acorn Advisory Capital first reported a position in Palvella Therapeutics in Q1 2018 and held it in 1 quarter.
  • Acorn Advisory Capital's Palvella Therapeutics position peaked at $188K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2018.

Based on Acorn Advisory Capital's 13F filing for Q2 2018, filed 8 Aug 2018.